Ma C, et al. - Given that the expression SATB2 is affected by molecular alterations and that inflammatory bowel disease-associated neoplasia differs from sporadic colorectal neoplasia regarding molecular alterations, researchers evaluated SATB2 immunohistochemistry as a biomarker of inflammatory bowel disease-associated neoplasia. They determined the SATB2 expression in 73 cases of inflammatory bowel disease-associated neoplasia including 37 dysplasia cases and 36 carcinomas. Further, they compared the expression patterns with 50 cases of nondysplastic colorectal mucosa in patients with active inflammatory bowel disease, 40 sporadic colonic polyps (20 conventional adenomas and 20 sessile serrated lesions/polyps), and 343 sporadic colorectal adenocarcinomas. As per observations, inflammatory bowel disease-associated colorectal dysplasia and adenocarcinoma commonly display loss of SATB2 expression. This expression seems to be a valuable ancillary biomarker when evaluating for inflammatory bowel disease-associated dysplasia.